- Home
- FT vs INBX Comparison
FT vs INBX Comparison
Compare FT & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- INBX
- Stock Information
- Founded
- FT 1988
- INBX 2010
- Country
- FT United States
- INBX United States
- Employees
- FT N/A
- INBX N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- INBX Health Care
- Exchange
- FT Nasdaq
- INBX Nasdaq
- Market Cap
- FT 185.7M
- INBX 218.9M
- IPO Year
- FT N/A
- INBX 2020
- Fundamental
- Price
- FT $7.55
- INBX $14.19
- Analyst Decision
- FT
- INBX Hold
- Analyst Count
- FT 0
- INBX 1
- Target Price
- FT N/A
- INBX N/A
- AVG Volume (30 Days)
- FT 63.0K
- INBX 80.6K
- Earning Date
- FT 01-01-0001
- INBX 11-14-2024
- Dividend Yield
- FT 7.85%
- INBX N/A
- EPS Growth
- FT N/A
- INBX N/A
- EPS
- FT N/A
- INBX 119.38
- Revenue
- FT N/A
- INBX $1,568,000.00
- Revenue This Year
- FT N/A
- INBX N/A
- Revenue Next Year
- FT N/A
- INBX N/A
- P/E Ratio
- FT N/A
- INBX $0.11
- Revenue Growth
- FT N/A
- INBX 19.24
- 52 Week Low
- FT $5.97
- INBX $10.80
- 52 Week High
- FT $7.23
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- FT 61.55
- INBX 47.10
- Support Level
- FT $7.19
- INBX $12.51
- Resistance Level
- FT $7.65
- INBX $14.86
- Average True Range (ATR)
- FT 0.09
- INBX 1.05
- MACD
- FT 0.04
- INBX -0.14
- Stochastic Oscillator
- FT 78.26
- INBX 38.89
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.